Chiasma partners with Roche in deal worth up to $600 million
The Israeli start-up and Swiss pharmaceutical giant will cooperate in the development of Chiasma's original drug and collaborate on future products.
The Israeli pharmaceutical start-up company Chiasma chalked up a significant achievement when it signed a commercialization agreement with Swiss pharmaceutical giant Roche for up to $530 million.
register with haaretz
Like us on Facebook and get articles directly in your news feed